Ultrasound-Driven Cavitation Reprograms Drug Response and Immune Sensitivity in Neuroendocrine Prostate Cancer

Acoustic cavitation is emerging as a surprisingly powerful tool in the therapeutic landscape of neuroendocrine prostate cancer (NEPC), a disease state notoriously resistant to conventional treatments. By combining nanometer-scale lipid microbubbles with targeted ultrasound, researchers are leveraging a physical mechanism to overcome some of the most entrenched biological barriers in aggressive prostate cancer.

At its core, cavitation enhances drug delivery through transient disruption of cellular membranes and intercellular junctions. This “sonoporation” effect increases intracellular chemotherapy uptake while simultaneously loosening structural proteins such as Claudin-3, allowing deeper drug penetration into tumor tissue. In preclinical NEPC models, this translated into a measurable increase in chemosensitivity, along with reduced invasive and migratory behavior, key hallmarks of aggressive disease.

However, the implications extend well beyond permeability. One of the most notable findings is the improvement in tumor oxygenation, with significant increases in intratumoral oxygen saturation following treatment. Hypoxia is a central driver of therapeutic resistance and lineage plasticity in NEPC, often reinforcing neuroendocrine features through pathways such as HIF-1α. By restoring perfusion and oxygen levels, cavitation appears to indirectly suppress these adaptive mechanisms, potentially contributing to the observed downregulation of neuroendocrine markers like NSE and MYCN, alongside restoration of tumor suppressors such as PTEN.

Equally compelling is the impact on the immune microenvironment. NEPC is typically immunologically “cold,” with limited responsiveness to immune checkpoint inhibitors. Yet, when cavitation is combined with immunotherapy, there is a marked increase in CD8+ T cell infiltration, a reduction in regulatory T cells, and elevated pro-inflammatory cytokines including TNF-α and IFN-γ. This suggests that cavitation may act as a form of in situ immune priming, converting an immune-excluded tumor into one more susceptible to checkpoint blockade.

In vivo results reinforce this multimodal effect. Tumor growth inhibition is significantly enhanced when cavitation is combined with chemotherapy and immunotherapy, with substantial improvements in survival. Interestingly, the approach also appears to mitigate systemic toxicity, as indicated by improved liver function markers and reduced oxidative stress, raising the possibility of more effective treatment at lower systemic doses.

Source.